UBS Declares Quarterly Coupon Payment on Exchange Traded Note: AMUB

UBS Investment Bank today announced the coupon payment for the ETRACS Alerian MLP Index ETN Series B (NYSE Arca: "AMUB"), traded on the NYSE Arca.

NYSE
Ticker

ETN Name and Prospectus
Supplement*

Coupon
Valuation
Date

Ex-
Date

Record
Date

Payment
Date

Coupon
Amount

Payment
Schedule

Current Yield
(annualized)**

AMUB

ETRACS Alerian MLP Index ETN Series B

11/17/25

12/01/25

12/01/25

12/09/25

$0.3168

Quarterly

6.66%

* The table above provides a hyperlink to the relevant prospectus and supplements thereto. For more information on the ETRACS ETN, see "List of ETNs ."

**"Current Yield (annualized)" equals the current Coupon Amount, multiplied by four (to annualize such coupon), divided by the Closing Indicative Value of the ETN on its current Coupon Valuation Date rounded to two decimal places for ease of analysis. The Current Yield is not indicative of future coupon payments, if any, on the ETN. You are not guaranteed any coupon or distribution amount under the ETN.

About ETRACS

ETRACS ETNs are senior unsecured notes issued by UBS AG, are traded on either NYSE Arca or NASDAQ, and can be bought and sold through a broker or financial advisor. An investment in ETRACS ETNs is subject to a number of risks, including the risk of loss of some or all of the investor's principal, and is subject to the creditworthiness of UBS AG. Investors are not guaranteed any coupon or distribution amount under the ETNs . We urge you to read the more detailed explanation of risks described under "Risk Factors" in the applicable prospectus supplement for the ETRACS ETN.

UBS AG has filed a registration statement (including a prospectus and supplements thereto) with the Securities and Exchange Commission, or SEC, for the offerings of securities to which this communication relates. Before you invest, you should read the relevant prospectus, along with the applicable prospectus supplement and pricing supplements to understand fully the terms of the securities and other considerations that are important in making a decision about investing in the ETRACS ETNs. The applicable offering document for each ETRACS ETN may be obtained by clicking on the name of each ETRACS ETN identified above. You may also get these documents without cost by visiting EDGAR on the SEC website at www.sec.gov . Alternatively, you can request the prospectus, the applicable prospectus supplement or pricing supplement, by calling toll-free (+1-877-387-2275). The securities related to the offerings are not deposit liabilities and are not insured or guaranteed by the Federal Deposit Insurance Corporation or any other governmental agency of the United States, Switzerland or any other jurisdiction.

About UBS

UBS is a leading and truly global wealth manager and the leading universal bank in Switzerland. It also provides diversified asset management solutions and focused investment banking capabilities. UBS manages 6.9 trillion dollars of invested assets as per the third quarter 2025. UBS helps clients achieve their financial goals through personalized advice, solutions and products. Headquartered in Zurich, Switzerland, the firm is operating in more than 50 markets around the globe. UBS Group shares are listed on the SIX Swiss Exchange and the New York Stock Exchange (NYSE).

In the US, securities underwriting, trading and brokerage activities and M&A advisor activities are provided by UBS Securities LLC, a registered broker/dealer that is a wholly owned subsidiary of UBS AG, a member of the New York Stock Exchange and other principal exchanges, and a member of SIPC ( http://www.sipc.org/ ). UBS Financial Services Inc. is a registered broker/dealer and affiliate of UBS Securities LLC.

This material is issued by UBS AG and/or any of its subsidiaries and/or any of its affiliates ("UBS"). This document was produced by and the opinions expressed are those of UBS as of the date of writing and are subject to change. It has been prepared solely for information purposes and for the use of the recipient. It does not constitute an offer or an invitation by or on behalf of UBS to any person to buy or sell any security. The information and analysis contained in this publication have been compiled or arrived at from sources believed to be reliable but UBS does not make any representation as to their accuracy or completeness and does not accept liability for any loss arising from the use hereof. Products and services mentioned in this material may not be available for residents of certain jurisdictions. Past performance is not necessarily indicative of future results. Please consult the restrictions relating to the product or service in question for further information. Alerian MLP Index and AMZ are trademarks of VettaFi and their use is granted under a license from VettaFi. VettaFi owns and administers the Alerian Index Series.

UBS specifically prohibits the redistribution or reproduction of this communication in whole or in part without the prior written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect.

© UBS 2025. The key symbol, UBS and ETRACS are among the registered and unregistered trademarks of UBS. Other marks may be trademarks of their respective owners. All rights reserved.

________________________________

1

Individual investors should instruct their broker/advisor/custodian to call us or should call together with their broker/advisor/custodian.

Media
Alison Keunen
+1-212-713-2296
alison.keunen@ubs.com

Institutional Investor 1
Tel. +1-877-387-2275

News Provided by Business Wire via QuoteMedia

UBS
The Conversation (0)
GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand

GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand

(TheNewswire) More people than ever taking GLP-1 drugs for weight loss Growing list of diseases now indicated as treatable with GLP-1 drugs Kelowna, British Columbia TheNewswire - June 17, 2026 Lexaria Bioscience Corp. (Nasdaq: LEXX) (the "Company" or "Lexaria"), a global innovator in drug... Keep Reading...
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand

GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand

More People Than Ever Taking GLP-1 Drugs for Weight Loss Growing List of Diseases Now Indicated as Treatable With GLP-1 Drugs KELOWNA, BC / ACCESS Newswire / June 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms,... Keep Reading...
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

600,000 New Wegovy® Pill Prescriptions Written in First Two Months KELOWNA, BC / ACCESS Newswire / April 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update of additional recent developments in the... Keep Reading...
Cartier Resources Grants Stock Options

Cartier Resources Grants Stock Options

Cartier Resources Inc. (TSX-V: ECR) (the " Company ") announces that the Board of Directors granted, on December 16, 2025, a total of 3,600,000 stock options to directors and officers and to one employee of the Company. Pursuant to the terms of the Company's stock option plan, each option... Keep Reading...
Canadian Investment Regulatory Organization Trade Resumption - AMT

Canadian Investment Regulatory Organization Trade Resumption - AMT

Trading resumes in: Company: AmeriTrust Financial Technologies Inc.TSX-Venture Symbol: AMTAll Issues: YesResumption (ET): 8:15 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair... Keep Reading...
AmeriTrust Announces it is Unaware of Any Material Change

AmeriTrust Announces it is Unaware of Any Material Change

TORONTO, ON / ACCESS Newswire / June 11, 2026 / AmeriTrust Financial Technologies Inc. (TSXV:AMT,OTC:AMTFF)(OTCQB:AMTFF)(Frankfurt:1ZVA) ("AmeriTrust", "AMT" or the "Company"), at the request of CIRO, wishes to confirm that the Company's management is unaware of any material change in the... Keep Reading...
AmeriTrust Announces First Quarter 2026 Financial Results

AmeriTrust Announces First Quarter 2026 Financial Results

TORONTO, ON / ACCESS Newswire / May 27, 2026 / AmeriTrust Financial Technologies Inc. (TSXV:AMT,OTC:AMTFF)(OTCQB:AMTFF)(Frankfurt:1ZVA) ("AmeriTrust", "AMT" or the "Company"), a fintech platform focused on automotive finance, announces that it has filed its interim Consolidated Financial... Keep Reading...
Steven Boms

From Skepticism to Action: Steve Boms on Canada’s Open Banking Turning Point

Canada is shaping its financial future through open banking.Steve Boms, executive director of FDATA North America, made a recent appearance on the Investing News Network podcast, where he detailed Canada’s long-awaited transition toward consumer-driven banking and how placing the Bank of Canada... Keep Reading...
AmeriTrust Announces 2025 Annual Financial Results

AmeriTrust Announces 2025 Annual Financial Results

TORONTO, ON / ACCESS Newswire / April 22, 2026 / AmeriTrust Financial Technologies Inc. (TSXV:AMT,OTC:AMTFF)(OTCQB:AMTFF)(Frankfurt:1ZVA) ("AmeriTrust", "AMT" or the "Company"), a fintech platform targeting automotive finance, is announcing that it has filed its audited Consolidated Financial... Keep Reading...

Charles Schwab's Money Talk Personal Finance Column Expands Bench of Expert Voices

Three new Certified Financial Planners ® join the column's roster of experts creating real-life financial education insight Charles Schwab today announced the addition of three new Certified Financial Planners® to Money Talk, Schwab's personal finance column designed to help everyday Americans... Keep Reading...

Interactive Chart

Latest Press Releases

Related News